Drugs / JI-101
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01149434 | Sep 2010 → Aug 2012 | colorectal cancer, neuroendocrine neoplasm, ovarian cancer | University of Utah | Terminated | No outcome recorded |
| Phase 1/2 | NCT00842335 | Feb 2009 → Jul 2010 | cancer | Jubilant Innovation Ltd. | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JI-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00842335 ↗ |
| Known as | Angiogenesis inhibitor ji-101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545155 ↗ |
| Known as | CGI-1842 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545155 ↗ |
| Action | Inhibit | “JI-101 is an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFRβ), and EphB4 receptor” NCT00842335 ↗3“Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL3545155 ↗ “Platelet-derived growth factor receptor beta inhibitor” CHEMBL3545155 ↗ “Ephrin type-B receptor 4 inhibitor” CHEMBL3545155 ↗ |
| Modality | Small molecule | — CHEMBL3545155 ↗ |
| Route | Oral | “when given orally” NCT00842335 ↗ |
| Target | EPHB4 | “Ephrin type-B receptor 4 inhibitor” CHEMBL3545155 ↗ |
| Target | KDR | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL3545155 ↗ |
| Target | PDGFRB | “Platelet-derived growth factor receptor beta inhibitor” CHEMBL3545155 ↗ |